Evidence map›Paper›PMID 39200211›Full record

ArticleBiomedicines2024

Erythropoietin Effect on Complement Activation in Chronic Kidney Disease.

Virginia Athanasiadou, Kleio Ampelakiotou, Eirini Grigoriou, Katherina Psarra, Alexandra Tsirogianni, Serena Valsami, Theodoros Pittaras, Eirini Grapsa, Maria G Detsika

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Virginia AthanasiadouDepartment of Nephrology, School of Medicine, Aretaieion University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0002-6092-688X
Kleio AmpelakiotouDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece.
Eirini GrigoriouDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece.
Katherina PsarraDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece.
Alexandra TsirogianniDepartment of Immunology and Histocompatibility, 'Evangelismos' General Hospital, 10676 Athens, Greece.ORCID 0000-0003-2531-4113
Serena ValsamiHematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0002-1034-6510
Theodoros PittarasHematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.ORCID 0000-0001-7178-2845
Eirini GrapsaDepartment of Nephrology, School of Medicine, Aretaieion University Hospital, National and Kapodistrian University of Athens, 11528 Athens, Greece.
Maria G Detsika1st Department of Critical Care Medicine and Pulmonary Services, GP Livanos and M. Simou Laboratories, Evangelismos Hospital, National and Kapodistrian University of Athens, 10675 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complement system is an important part of innate immunity. Despite its known protective role, the complement system may contribute to increased inflammation and tissue injury in cases where its balanced activation is disrupted. The kidneys have been shown to be largely affected by complement dysregulation. The aim of the present study was to investigate the effect of erythropoietin administration, on the complement system, in chronic kidney disease patients. The study involved 20 patients with CKD who received erythropoietin and measurements of levels of complement factors C3a and C5a and complement regulatory proteins (CregPs) CD55, CD46, and CD59. An increase in serum C3a and C5a levels was observed in response to EPO therapy. The increase in C3a was statistically significant (

Indexed as

chronic kidney diseasecomplementerythropoietinlymphocytes

Identifiers

PMID39200211
PMCPMC11351309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.